Celularity Inc - Class A

CELU F | $3.31 9.7K

(0.0% 1d) (-33.0% 1m) (366.7% 1y) (0.0% 2d) (0.0% 3d) (-22.2% 7d) (63.83% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 716,304,654
https://celularity.com
Sec Filling | Patents | 225 employees

(US) Celularity, Inc. headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified natural killer (NK) cells, genetically-modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

genetic cancer t-cell

add to watch list Paper trade email alert is off

Press-releases

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
CELU F | $3.31 9.7K

| -22.22% | O: -4.44% H: 5.58% C: -2.33%
sales first for advanced

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
Published: 2024-04-08 (Crawled : 13:00) - globenewswire.com
CELU F | $3.31 9.7K

| -31.1% | O: 5.51% H: 5.78% C: 3.36%
natural cell

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L
Published: 2024-03-26 (Crawled : 13:00) - globenewswire.com
CELU F | $3.31 9.7K

| -33.59% | O: 1.52% H: 0.0% C: -5.98%
biovance services approval system

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
Published: 2024-03-20 (Crawled : 13:00) - globenewswire.com
CELU F | $3.31 9.7K

| -32.95% | O: 4.02% H: 0.74% C: 0.74%
pda-002 fda drug designation

Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit
Published: 2024-03-14 (Crawled : 13:00) - globenewswire.com
CELU F | $3.31 9.7K

| -39.55% | O: 0.35% H: 2.75% C: -1.89%
ceo cell potential

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
Published: 2024-03-12 (Crawled : 13:30) - globenewswire.com
CELU F | $3.31 9.7K

| -49.71% | O: 0.72% H: 3.99% C: -15.91%
ceo congress world therapeutics

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells
Published: 2024-03-07 (Crawled : 14:30) - globenewswire.com
CELU F | $3.31 9.7K

| -18.6% | O: 0.0% H: 27.91% C: 27.67%
cancer cell tumor therapy

Celularity Announces 1-for-10 Reverse Stock Split
Published: 2024-02-23 (Crawled : 21:00) - globenewswire.com
CELU F | $3.31 9.7K

| Email alert Add to watchlist

Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease
Published: 2024-02-14 (Crawled : 21:00) - globenewswire.com
CELU F | $3.31 9.7K

| 775.0% | O: -0.43% H: 4.92% C: 2.69%
disease ocular cell treatment

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline
Published: 2024-02-01 (Crawled : 14:00) - globenewswire.com
CELU F | $3.31 9.7K

| 821.05% | O: 7.89% H: 37.93% C: 19.05%
sales first year pipeline commercial advanced

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001493152-24-014945	4	2024-04-17	2024-04-13	Sell	F	20	21085
0001493152-24-014946	4	2024-04-17	2024-04-13	Sell	F	576	38373
0001493152-24-014943	4	2024-04-17	2024-04-13	Sell	F	360	23983
0001493152-24-014947	4	2024-04-17	2024-04-13	Sell	F	1154	2855889
0001493152-24-014944	4	2024-04-17	2024-04-13	Sell	F	268	19472